Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec, 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer Read
- Dec. 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- Dec. 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- Dec. 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
- Dec. 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
- Dec. 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
- Dec. 3, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- Nov. 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
- Nov. 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results Read
- Oct. 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Oct. 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Oct. 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China Read
- Sept. 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read
- Sept. 6, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer Read
- Aug. 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results Read
- July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada Read
- July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
- July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT trial) Read
- June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 trial of PB272 in Combination with trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting Read
- May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read
- May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results Read
- May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 Read
- April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
- April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Read
- April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as treatment Options for Patients with Breast Cancer Brain Metastases Read
- March 6, 2018 - Puma Biotechnology to Present at Cowen's Annual Healthcare Conference Read
- March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Read
- Feb. 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
- Feb. 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read
- Feb. 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Read
- Feb. 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China Read
- Jan. 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature - Read
- Jan. 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel Read
- Jan. 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- Jan. 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read